Because of the difficulties and high costs associated with obtaining human tissue and cell samples for drug research purposes, pharmaceutical R&D has come to rely on non-human biology-based testing and computational prediction methods for drug target research, and safety and efficacy screening of potential new therapies. This has led to significant unreliability in predicting drug behaviour in man, contributing to high failure rates in clinical development.
For this reason, CellMade has focused on enabling drug discovery researchers to gain easy access to human primary cells and co-culture systems, and to use these systems to identify biomarkers that could be reliable indicators of drug behaviour in vivo. By generating data from primary human cells in early drug discovery, we can enable better candidate selection decisions, improve the design of preclinical studies and help to de-risk clinical development stages.
There is a growing need for effective companion tests for anti-inflammatory drugs, as patients and FDA concerns grow regarding the costs and unwanted side effects of the TNF-alpha antagonists. This move towards more “personalised medicine” is one area where Cellmade’s technology could be used to identify people who would benefit from such treatments, in addition to giving early warning signs of toxicity before clinical symptoms develop.